Innate Pharma (OTCMKTS:IPHYF) Shares Down 19.6%

Innate Pharma S.A. (OTCMKTS:IPHYF)’s stock price traded down 19.6% on Friday . The stock traded as low as $2.13 and last traded at $2.13. 2,000 shares changed hands during mid-day trading, an increase of 278% from the average session volume of 529 shares. The stock had previously closed at $2.65.

Innate Pharma Stock Performance

The business’s 50 day simple moving average is $2.60 and its 200-day simple moving average is $2.62.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.